Microvesicle RNA Biomarkers for Kidney Transplant Rejection Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing kidney transplant rejection, particularly acute rejection, are invasive, costly, and lack sensitivity and specificity, necessitating an accurate and non-invasive approach for early detection.
Innovation Solution
The use of microvesicular RNA biomarkers, such as CXCL11, CD74, IL32, and STAT1, analyzed from biological samples, to generate a score through an algorithm for identifying and predicting kidney transplant rejection, allowing for the differentiation between antibody-mediated and cell-mediated rejections without the need for renal biopsies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If kidney allograft biopsies are performed for diagnosis of acute rejection, then diagnostic accuracy is improved, but invasiveness and risk of complications increase
Solution Approach 1:
The patent uses microvesicles as intermediary carriers that transport RNA biomarkers from kidney allograft tissue into the bloodstream. These microvesicles serve as a mediator that allows indirect detection of rejection through blood samples, eliminating the need for direct tissue biopsy while preserving diagnostic accuracy
Solution Approach 2:
The patent analyzes RNA biomarkers within microvesicles that are released from kidney allograft tissue during rejection. These microvesicles contain molecular copies of the tissue's genetic signature, allowing diagnostic information to be obtained from blood samples rather than requiring direct tissue sampling
2Loss of time
If repeated kidney biopsies are performed for monitoring rejection, then early detection capability is improved, but cost and negative complications increase
Solution Approach 1:
The patent enables repeated monitoring by analyzing RNA biomarkers in circulating microvesicles from blood samples. This approach creates a reusable, non-invasive sampling method that can be performed repeatedly over time without accumulating the costs and complications associated with repeated tissue biopsies
Solution Approach 2:
The patent utilizes the body's natural process of releasing microvesicles containing RNA biomarkers into the bloodstream during rejection. This self-service mechanism provides continuous diagnostic information through readily accessible blood samples, eliminating the need for invasive procedures to obtain monitoring data
3Ease of operation
If traditional biomarkers (serum creatinine and urinary protein excretion) are used to monitor kidney graft function, then ease of operation is improved, but sensitivity, specificity and predictive ability worsen
Solution Approach 1:
The patent transitions from analyzing traditional physiological parameters (serum creatinine, urinary protein) to analyzing molecular parameters (RNA biomarkers within microvesicles). This parameter change enables detection of rejection at the molecular level, providing superior sensitivity and specificity while maintaining the ease of blood sampling
Data Source
AI summary
The present disclosure relates to methods of identifying and treating kidney rejection in a subject comprising analyzing microvesicular RNA, cell-free DNA or the combination of microvesicular and cell-free DNA.”